2025-07-07 - Anatomic Pathology sCRG Meeting

2025-07-07 - Anatomic Pathology sCRG Meeting

Group name

Anatomic Pathology sCRG

Date

07-07-2025 16:30 - 17:30 CEST

Attendees

@Thomas Ruediger @mary edgerton @Thomas Ruediger @Elaine Wooler @Stefan Dubois @Karim Nashar @Paul @Jieun Hwang @Scott Campbell 



Apologies



Recording (Cloud)



Discussion items

Item

Description

Owner

Notes

Action

Item

Description

Owner

Notes

Action

1

Updates

@Scott Campbell 

2

Immunohistochemistry for digital path - RECAP

@Scott Campbell 

Scope work and work plan

  • Use p16 as a starting point.

  • What is the overarching use case:

  • Clinical documentation?

  • Digital path to build clinical documentation?

  • Research?

  • Example paper for background:

https://www.bgcs.org.uk/wp-content/uploads/2019/05/BAGP-UKNEQAS-cIQC-project-p16-interpretation-guide-2018.pdf

Sample answer set for digital path use case:

Answer set: positive, negative, null (absent), wild type, equivocal with modifiers of: nuclear, cytoplasmic, membranous, diffuse, patchy, focal, strong, weak, moderate





Use cases:

  1. DIgital path workflows require SCT concepts to identify what stains are being viewed at any given time.  High volume IHC stains do not have SCT concepts....

    A slide being scanned would communicate to the scanner/LIS/Digpath software what is being viewed by the pathologist.  (Is this DICOM use?)


  2. DICOM (slide label/metadata) → WSI annotation:  Substance → observable


  3. Antigen vs antibody?  Antigen targeting the antibody (detection methods/system not modeled here)...so, create antibody substances.


  4. Consolidate list of antibody candidates from Leica, Duke, Nictiz for next meeting.  Ultimately, antigens WILL need to be authored, as well. This will be important in disorder content/modeling



Lists of candidate concepts

@Scott Campbell 



  1. Duke - Immunostain volumes.xlsx



  2. Palga - 20250327 Proteinen in PPM voor SCT Int all_rubrics.xlsx

    Immunopanel PMC.xlsx


    Property - Presence 
    Presence of what? - p16 antibody

    Workflow: 

    1. Antibody applied to tissue

    2. Antibody binds to antigen (protein) on structure of interest

    3. Antibodys have "subtypes"/monoclonal antibodies that a specific to sections of the protein (target)

    4. So, the antigen is the target.  The clone(s) is important in specificity/sensitivity (interpretation precision (@Scott Campbell words))

    5. Chromagen indicates the color of the antibody/antigen reaction.

OK.  Goal...model the antibodies and relevant closes.  The observable entity is the observation of the epitope of interest.  Information model carries the details of the clones.

Meeting Files

  File Modified

Microsoft Excel Spreadsheet Immunopanel PMC.xlsx

2025-Jul-07 by Scott Campbell

Microsoft Excel Spreadsheet 20250327 Proteinen in PPM voor SCT Int all_rubrics.xlsx

2025-Jul-07 by Scott Campbell

Microsoft Excel Spreadsheet Immunostain volumes.xlsx

2025-Jul-07 by Scott Campbell



Previous Meetings

TitleCreatorModified
No content found.

Copyright © 2025, SNOMED International